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National Health System. The objective of this research is to analyze the differ-
ences in adoption of BS among the different Spanish Autonomous Communities 
(Regions). Methods: Ecologic design. A retrospective analysis of the Spanish 
2011 Health System Survey was conducted to estimate the prevalence of adult 
PWI for BS in each Region. The results were therefore extrapolated to the total 
regional adult population reported by the National Institute of Statistics for 2011. 
The total number of bariatric surgeries by Regions during 2011were retrieved 
from the database of the National Health Ministry (ICD-9-CM: 44.31, 44.39, 44.38, 
44.95 and 44.69) Results: Variation in the annual provision of BS was large, rang-
ing from 0.81% of patients with indication for Murcia, to 0.11% in Navarra. For 
the rest of Regions, the percentage of PWI operated in 2011 was: Madrid= 0.62%; 
Castilla y León= 0.60%; Aragón= 0.35%; Cataluña= 0.33%; Pais Vasco= 0.32%; Com. 
Valenciana= 0.30%; Cantabria= 0.30%; Canarias= 0.30%; Extremadura= 0.23%; 
Galicia= 0.22%; Asturias= 0.19%; Andalucía= 0.18%; Castilla La Mancha= 0.15%; 
Baleares= 0.14% and La Rioja= 0.13%. ConClusions: These results raise the 
hypothesis that living in a certain Region may strongly affect the probability of 
a PWI receiving BS. In such case, this variability should be tackled, particularly 
in a country where most patients are supposed to have access to this treatment 
without any copayment. Further research with more accurate estimations and 
multilevel analysis models would be desirable to confirm these results.
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objeCtives: Recent debate on the long-term effectiveness of some orphan medic-
inal products (OMPs) led us to question whether the initial standards for clinical 
evidence for OMPs, set by EMA at the time of marketing authorization, are too low. 
Therefore, the aim of this study was to quantitatively evaluate the characteristics 
and quality of clinical evidence that is presented for OMPs to obtain marketing 
authorization in Europe. Methods: We quantitatively assessed the characteris-
tics and quality of clinical evidence of the pivotal studies of 64 OMPs as described 
in the European Public Assessment Report and/or the Scientific Discussion docu-
ment prepared by the Committee for Human Medicinal Products of the EMA using 
a new and validated instrument. Results: The 64 OMPs were altogether author-
ized for 78 orphan indications, for which 117 studies were identified as ‘pivotal’ 
or ‘main’ studies. In approximately two thirds of the studies, the allocation was 
randomized (64.8%) and a control arm was used (68.5%). Half of the studies applied 
some type of blinding. Only a minority (26.9%) of the studies included a Quality-
of-Life (QoL) related endpoint, of which a third claim an improvement in QoL. 
Upon analyzing the quality of reporting, we found that some aspects (i.e. the 
endpoints, the sampling criteria, and the interventions) are well described, 
whereas other items (i.e. a description of the patients and of potential biases) 
are not reported for all studies. ConClusions: In conclusion, the pivotal studies 
that are the basis for marketing authorization of OMPs are a cause for concern, 
as they exhibit methodological flaws. Additionally, there are shortcomings in the 
reporting of those studies that complicate the interpretation. A more demanding 
regulatory process for OMPs is needed to guide evidence-based clinical decision-
making.
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objeCtives: As costs of health care continue to rise, payers need to quantify the 
potential patient population for a new treatment. In the case of a novel treatment 
for intractable pain that would be for end of life cancer patients, it was necessary 
to consider alternative methods for calculating the potential patient population 
size. This study determined different approaches for identifying patient subpopu-
lations in cancer for ‘end-of-life’ pain therapies Methods: PAREXEL conducted a 
literature search on the number of cancer pain patients with intractable pain. Data 
was found on cancer patients with pain but not those at the end of their lives with 
intractable pain. Alternative measures were considered, and cancer mortality data 
was identified as a surrogate for end of life cancer patients. The WHO’s guidelines 
on cancer pain estimate that 10 to 25% of cancer pain patients have intractable 
pain. Based on such surrogate measures, we were able to determine an estimated 
number of cancer patients with intractable pain at the end of their lives. Results: 
Prior to this study, the target patient population was estimated to be 156,000 in 
the US and an equivalent number in Germany, UK, Spain and France. However, 
based on the surrogate measures, the results were much lower: 30,000 in the US 
and 31,000 in the 4 EU countries. These numbers were validated by interviewing 22 
pain clinicians in the US and EU and 23 payers in the US and EU. ConClusions: 
By providing payers with accurate estimates of potential patient populations they 
will be better able to determine the cost implications of covering novel treatments. 
Given that the care provided to patients at the end of their lives is usually signifi-
cantly higher than at any other time, treatments for end of life care have economic 
implications for payers.
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objeCtives: To identify and compare all costs related to preparing and administrat-
ing MabThera for the intravenous and subcutaneous formulations in Dutch hema-
tological patients. The a priori notion is that the costs of subcutaneous MabThera 
In 2011, a total of 630 products (all therapeutic classes) were prescribed. The most 
often other prescribed classes in 2011 were gastrointestinal tract products (14.60%), 
cardiovascular agents (11.11%) and antimicrobial products (9.52%). The most fre-
quently prescribed subclasses were HMG-CoA reductase inhibitors (statins), anal-
gesic combinations, non-selective COX-inhibitors and selective serotonin re-uptake 
inhibitors. The total amount claimed from the medical insurance scheme for all the 
products was R73013.71, however, only R37553.24 was paid out. Appetite suppres-
sants were excluded from patients’ medical insurance benefits. ConClusions: A 
limited number of strictly regulated appetite suppressants were prescribed. Appetite 
suppressants that patients can buy over-the-counter were not included in this study. 
Pseudoephedrine has recently been rescheduled to be more strictly controlled due 
to its abuse potential. Further consumer studies on appetite suppressants which 
include clinical information will provide a useful insight into the role of these prod-
ucts in weight loss efforts.
PSY71
analYSiS of the reiMburSed PSoriaSiS Market in hungarY between 
2007 and 2011
Ecseki A., Nagy Z.B., Becsi R., Gerencsér Z., Rozsa P., Toth I.
MediConcept Ltd., Budapest, Hungary
objeCtives: Psoriasis is a chronic skin disease of scaling and inflammation, typi-
cally characterized by erythematous papules and plaques with a silver scale. In 
Hungary, approximately 150.000 – 200.000 people are affected. We sought to evalu-
ate the available reimbursed psoriasis treatment options, the economic impact 
of the disease, and in general we attempted to see beyond the market trends and 
patients characteristics observed in the analysed dataset. Methods: Data were 
derived from the nationwide dataset of the Hungarian National Health Insurance 
Fund Administration, the single health care financing agency of Hungary. Data 
were evaluated according to sex, age, geographical region, type of care and specialty 
of the prescribing physician. The analysis covers data of all reimbursed pharma-
ceuticals and other medical services between 1 January 2007 and 31 December 
2011. Results: The median age was between 51 and 55 years. A bimodal age of 
onset has been recognised in several large studies, but in this patient cohort peo-
ple between the ages of 30 and 69 were overrepresented. We found no significant 
deviation between counties, but there is a clear seasonality in the data. During 
each year of the analysed period the number of patients who redeemed at least 
one reimbursed drug fell short compared to the prevalence based estimates. At 
any given time close to 80% of the patients did not receive any reimbursed treat-
ment and the number of sold packages continuously decreased over the 5-year 
period. The introduction of biologic treatments also significantly affected the mar-
ket. ConClusions: To our knowledge, no systematic empirical research exists 
addressing the question of how psoriasis market changed over the time in Hungary. 
The data suggest relatively poor adherence to treatment regimens frequently seen 
and documented in other studies as well.
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objeCtives: Although opioids are a well-accepted and effective method for pain 
management, it is still a challenge for physicians to find adequate treatment 
schemes in non-malignant pain. Inadequate treatment might impact quality of 
life and induce social and psychological problems. Aim of this survey was to describe 
treatment patterns of chronic back pain (CBP) in Germany. Methods: In a cross-
sectional, non-interventional survey n= 4,283 German physicians were asked to 
report experiences with strong opioids in CBP. Statistical analysis was performed to 
analyze relationships between strong opioids and potential side effects. Results: 
The majority of physicians (54.4%) at least partly accept strong opioid therapy in CBP 
noting treatment benefits in 69.6%. Most prescribed therapies are non-opioids like 
NSAIDs/COX-2 (55.1%) and physiotherapy (47.7%). 22.7% of all CBP receive strong opi-
oids (26.0% fentanyl, 19.9% oxycodone/naloxone, 17.8% oxycodone, 13.9% hydromor-
phone, 13.8% burprenorphine, 13.7% morphine, 7.3% tapentadol, 1.8% L-methadone). 
16.5% are treated in monotherapy, 23.6% with multimodal treatment. 67.5% show 
a reduction in pain intensity ≥ 50%. 25.8% need strong opioids for longer than 12 
months. 26.2% need an increased dosage. Furthermore, 20.2% of patients experience 
a decrease in efficacy, which leads to opioid rotation (15.1%). 23.4% have persistent 
side effects (25.3% never, 46.4% temporary) wherefore 16.1% switch and 15.2% with-
draw the treatment. Most side effects are observed near start of therapy, with con-
stipation being the most common and resistant side effect (49.1%). After treatment 
discontinuation, pain status is considerable worsened in 34.3%. Correlation analysis 
shows that morphine has the highest probability of side effects when compared 
to oxycodone and oxycodone/naloxone. ConClusions: Although physicians see 
the medical need, CBP patients seem not to be overly treated with strong opioids. 
Obviously, morphine is not the treatment of first choice. Treatments chosen strongly 
depend on physician specialty. As anticipated, constipation is the most common 
and resistant side effect.
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objeCtives: Geographical variations in medical practice are expected to be small 
when the evidence about a particular technology is abundant. This would be the 
case of bariatric surgery (BS), which has been demonstrated to be an effective 
intervention to promote weight-loss in patients with indications for this pro-
cedure (PWI). Moreover, BS has recently proven to be cost-effective and drive 
long-term savings, compared to a “do-nothing” intervention, for the Spanish 
